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Frederic Baron,1,2 Rainer Storb3,4Mesenchymal stromal cells (MSCs) represent a heterogeneous subset of multipotent cells that can be
isolated from several tissues including bone marrow and fat. MSCs exhibit immunomodulatory and anti-
inflammatory properties that prompted their clinical use as prevention and/or treatment for severe graft-
versus-host disease (GVHD). Although a number of phase I-II studies have suggested that MSC infusion
was safe and might be effective for preventing or treating acute GVHD, definitive proof of their efficacy
remains lacking thus far. Multicenter randomized studies are ongoing to more precisely assess the impact
of MSC infusion on GVHD prevention/treatment, whereas further research is performed in vitro and in
animal models with the aims of determining the best way to expand MSCs ex vivo as well as the most efficient
dose and schedule of MSCs administration. After introducing GVHD, MSC biology, and results of MSC
infusion in animal models of allogeneic hematopoietic cell transplantation, this article reviews the results
of the first clinical trials investigating the use of MSC infusion as prevention or treatment of GVHD.
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Allogeneic hematopoietic cell transplantation
(HCT) is the treatment of choice for many patients
with life-threatening hematologic diseases such as
patients with acquired lack of marrow function, inborn
errors, and hematologic malignancies [1]. In the latter
case, eradication of malignancies depends not only on
the high-dose chemo/radiotherapy given in the condi-
tioning regimen, but also on donor T and natural killer
(NK) cells present in the graft (GVTeffect) [2-7]. Initial
evidence for GVT effects in humans came from studies
reporting reduced leukemic relapse rates in allografted
patients who developed acute and/or chronic GVHD
(aGVHD, cGVHD, vide infra) compared with those1Department of Medicine, Division of Hematology,
rsity and CHU of Liege, Liege, Belgium; 2GIGA I3,
rsity of Liege, Liege, Belgium; 3Fred Hutchinson Cancer
rch Center, Seattle, Washington; and 4University of
ington, Seattle, Washington.
isclosure: See Acknowledgments on page 835.
dence and reprint requests: Frederic Baron, MD, PhD,
rsity of Liege, Department of Hematology, CHU Sart-
n, 4000 Liege, Belgium (e-mail: f.baron@ulg.ac.be).
ugust 2, 2011; accepted September 10, 2011
merican Society for Blood and Marrow Transplantation.
by Elsevier Inc. All rights reserved.
/$36.00
6/j.bbmt.2011.09.003who did not [8,9], and higher risk of relapse in patients
given T cell–depleted grafts or grafts from syngeneic
donors [10-13]. Further, direct evidence for antitumor
effects of allogeneic cells came from observations that
infusion of donor lymphocytes could induce complete
remissions in a number of patients with hematologic
malignancies who had relapsed after allogeneic HCT
[4,14-16]. These observations were the basis for the
development of allogeneic HCT following reduced-
intensity (RIC) or truly nonmyeloablative conditioning
regimen, in which the burden for tumor eradication re-
lies mainly (RIC) or nearly exclusively (nonmyeloabla-
tive conditioning) on GVT effects [17-26].
Unfortunately, donor-versus-host alloreactivity is
not always limited to destruction of tumor cells, but
can also be the cause of GVHD, a potentially life-
threatening complication of allogeneic HCT, in which
donor lymphocytes destroy host organs [27]. GVHD
has been classically divided into 2 syndromes:
aGVHD, occurring within 100 days after transplanta-
tion, and cGVHD developing thereafter [27]. How-
ever, GVHD with characteristics of the chronic form
can occur as early as 50 days after HCT, whereas
aGVHD may occur beyond day 100 after HCT in
patients given nonmyeloablative or RIC [28], often
upon discontinuation of postgrafting immunosuppres-
sion or at the time of conversion of mixed donor T cell
chimerism to full donor T cell chimerism [29,30].
These observations prompted the development of
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Institutes of Health Consensus Conference [31]. This
classification recognized 2 categories of GVHD:
aGVHD defined as GVHDwithout features consistent
with cGVHD comprising classic aGVHD occurring be-
fore day 100, and late a GVHD occurring after day 100;
and cGVHD comprising classic cGVHD defined as
cGVHD without signs of aGVHD and overlap syn-
drome in which features of both aGVHD and cGVHD
coexist [31]. Interestingly, 3 recent reports have ob-
served that classic cGVHDwas significantly associated
with GVT effects after allogeneicHCT following RIC
or nonmyeloablative conditioning, whereas aGVHD
and late aGVHD were not [32-34].
In mice, the pathogenesis of aGVHD includes 3
sequential phases [35,36]. In the first phase, the
conditioning regimen (and in particular total body
irradiation [TBI]) induces tissue damages that activate
host tissues. Activated host cells secrete several inflam-
matory cytokines and growth factors, such as tumor
necrosis factor alpha (TNF-a) and interleukin-1
(IL-1) (‘‘cytokine storm’’), leading to increased expres-
sion of adhesion and cell surface recognitionmolecules
by host cells, thereby enhancing the recognition of
host minor or major histocompatibility (MHC) anti-
gens by mature donor T cells. Antigen presentation
(mainly by host dendritic cells that are essential to
induce GVHD in mice [37]), as well as activation, pro-
liferation and differentiation of donor T cells occur in
the second phase. Finally, in the third phase, activated
T cells and TNF-a induce organ damage and the
clinical manifestations of aGVHD [35,36].
Althoughseveral reportshaveobservedanassociation
between the intensity of the cytokine storm and the prob-
ability ofGVHD inhumans [38-41], the observation that
donor lymphocyte infusions givenwithout any preceding
conditioning induced GVHD in one-half of the
patients demonstrated that aGVHD could occur
without any cytokine storm in humans, contrary to
what has been observed in many murine models.
The pathophysiology of cGVHD remains not fully
understood. It is generally accepted that donor T cells
(and particularly CD41 T cells [42]) are largely
involved in the pathophysiology of cGVHD, because
profound T cell depletion leads to a very low incidence
of cGVHD even in the HLA haploidentical setting
[43], and because infusion of peripheral blood stem
cells (PBSC, containing 10 times more T cells than
marrows) or addition of donor buffy coat cells
increased the incidence of cGVHD in comparison to
patients receiving allogeneic marrows alone [44,45].
In addition, donor lymphocyte infusion induces
cGVHD in approximately 60% of the recipients [4].
HLA disparities between donor and recipient are also
a risk factor of cGVHD (although to a lesser extent
than for aGVHD [46]), suggesting that cGVHD
manifestations are because of donor T cells recogniz-ing allogeneic antigens (such as major or minor
histocompatibility antigens). The role of minor histo-
compatibility antigen disparities is supported by the
higher incidence of cGVHD in male patients given
grafts from female donors versus other gender combi-
nations [46], because the Y chromosome encodes the
HY antigen that can act as a minor histocompatibility
antigen [47]. Host thymus integrity could also play
a role, as suggested by the lower incidence of cGVHD
in younger recipients [27,46]. A possible role of the
thymus could be the deletion of ‘‘auto’’ reactive
clones during negative selection, and perhaps the
generation of regulatory T cells [48,49]. However,
a recent study observed a similar incidence of
cGVHD in patients with thymic function (assessed
by measuring signal joint T cell receptor excision
circle levels) below or above the median on day 100
after HCT [50]. It has also been suggested that B cells
might play a role in the physiology of cGVHD [51]. In-
deed, deposition at the dermoepidermal junction of
IgM and complement was frequently observed in pa-
tients with chronic cutaneous GVHD [52], whereas
antibodies directed against HY proteins have been
found in male cGVHD patients given allo-HCT
from female donors [53]. More arguments in favor of
a role of B cells in the physiology of cGVHD include
a lower incidence of cGVHD in patients given rituxi-
mab (a monoclonal antibody directed against the
CD20) [54], and reports of improvement of chronic
skin GVHD after rituximab administration [55].
Dependingon theextentofHLAmatchingbetween
donor and recipient, the intensity of the conditioning
regimen, the stem cell source, the graft composition,
the patient age, and the gender combination, the inci-
dents of grade II-IV aGVHD and extensive cGVHD
have varied from 10% to 70%. The current standard
of care for GVHD prevention in patients receiving
grafts from HLA-matched donors has remained in
most centers the combination of a calcineurin inhibitor
(cyclosporin or tacrolimus) with an antimetabolite
(short methotrexate in case of myeloablative bone mar-
row/PBSCtransplantationormycophenolatemofetil in
case of nonmyeloablative or cordblood transplantation)
[23,56-59]. Further progress in GVHD prevention
might involve the use of antithymocyte globulin
(ATG) [60-63], or mammalian Target of Rapamycin
(mTOR) inhibitors such as sirolimus [64].
The treatment for aGVHD generally involves
high-dose steroids [27,65]. Specifically, the most
common primary therapy for aGVHD consists of
methylprednisolone, 2 mg/kg/day for 7 to 14 days,
followed by gradual dose reduction if the GVHD
improves, although 1 recent paper has suggested that
initial treatment with 1 mg/kg/day methylprednisolone
was as efficient as initial treatment with 2 mg/kg/day in
patients with grade II aGVHD [66]. Corticosteroids
produce durable complete responses in 20% to 75% of
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in patients with lower gut aGVHD [68]. In patients not
responding to steroids, outcome is dismal [27]. Specifi-
cally, patients with grade II, III, and IV steroid-
refractory aGVHD had median survivals of 4.1, 3.6,
and 2.7 months, respectively, after salvage therapy
with ATG [69], whereas no other second-line treat-
ments have proven to do better than what has been
achieved with ATG for gut or liver steroid-refractory
aGVHD [65]. First-line treatment for extensive
cGVHD is generally based on steroids, often combined
with cyclosporine or tacrolimus [70]. Unfortunately,
with this regimen only 20% to 50% of the patients
achieve complete resolution of GVHD and withdrawal
of all systemic treatment within 2 to 3 years [71,72].
Even though a number of immunosuppressive agents
have demonstrated therapeutic activity in steroid-
refractory cGVHD, the prognosis of patients with
steroid-refractory cGVHD remains unsatisfactory
with 2-year survival ranging from 41 to 85 with salvage
therapy [73-75]. These data stress the need for novel
therapies for both aGVHD and cGVHD.BIOLOGYOF MSC
The bone marrow microenvironment is composed
of different elements that support hematopoiesis and
bone homeostasis. Among them, bone marrow stroma
contains an adherent fibroblast-like population, repre-
senting 0.01% to 0.001% (depending on age) of mar-
row cells that, under appropriate conditions, retain
the ability to differentiate into a number of cell line-
ages, including bone, cartilage, tendon, muscle, or
adipose tissue [76,77]. These cells, first identified by
Friedenstein et al. [78,79] in 1968, have been termed
bone marrow ‘‘stromal cells,’’ ‘‘mesenchymal stem
cells,’’ or ‘‘multipotent mesenchymal stromal cells’’
(MSCs) [80,81]. After ex vivo expansion, human
MSCs have a fibroblastic-like morphology, and are
uniformly positive for CD73 (SH3 or SH4), CD90,
CD105 (SH2), CD29, CD44, CD71, CD106,
CD120a, CD124, and CD166, but are negative for
common hematopoietic markers like CD14, CD45,
or CD34 [80-83]. In addition, human MSCs express
HLA-class I and can be induced to express HLA-
class II by interferon gamma (IFN-g) [80]. However,
MSCs are only weakly immunogenic in humans,
even when infused after allogeneic HCT [84,85].
In recent years, further interest in MSCs has been
raised by the observation that they exhibit profound
immunosuppressive abilities in vitro and in vivo [80].
In vitro, MSCs inhibited T cell proliferation in mixed
lymphocyte reactions or induced by mitogens [86,87],
and inhibited naive and memory T cell responses to
their cognate antigens [88]. Interestingly, 1 study
showed that MSCs had little impact on T cell
responses to cytomegalovirus and Epstein-Barr virus,while exhibiting strong immunosuppressive effects on
alloreactive T cells [89]. The degrees of inhibition
were dose-dependent and independent of HLA-
matching. Further, MSCs could induce regulatory
T cells, as evidenced by the increased proportion of
CD41CD251FoxP31 cells in mixed lymphocyte
cultures in the presence of MSCs [82,90]. MSCs also
inhibited IL-2 (or IL-15) induced NK cell prolifera-
tion, although the inhibition was only partial [91],
whereas the impact of MSCs on B cell proliferation
has remained debated [92,93]. How MSCs modulate
T cell activation and immune response has remained
an open question. Several groups have reported that
T cell modulation was contact independent and
involved soluble factors [92,93]. Because MSC culture
medium was only mildly immunosuppressive [94],
one could hypothesize that MSCs produce these im-
mune factors in crosstalk with immune cells. Potential
soluble factors involved could include transforming
growth factor beta (transforming growth factor-b), he-
patocyte growth factor, bonemorphogenetic protein 2,
prostaglandin E2, indoleamine 2,3 dioxygenase, nitric
oxide, IL-10, heme oxygenase-1, HLA-G5, and
galectin-1 [81,82,95-98]. It has been shown that the
inhibition of lymphocyte proliferation in vitro by
nonactivated MSCs was neither because of induction
of lymphocyte apoptosis nor induction of T cell
tolerance, but instead due to induction of anergy of
activated T cells that could be reinitiated after MSCs
withdrawal [86,88,99]. Finally, MSCs inhibited
differentiation of both CD341 cells and monocytes
into mature dendritic cells, decreased their ability to
activate T cells, and favored the induction of
regulatory antigen-presenting cells [90,100-102].
In mice, MSC infusion prolonged cardiac allograft
survival through the generation of regulatory T cells
[103]; it also prevented the rejection of allogeneic B16
melanoma cells (H-2b/b) in immunocompetent C3H
mice (H-2k/k) [104], improved autoimmune enteropathy
and experimental colitis [105,106], and ameliorated
experimental autoimmune encephalomyelitis by
inducing T cell anergy [107]. In contrast, MSCs failed
to inhibit activated T cells in a mouse model of
collagen-induced arthritis [108]. Finally, infusion of
ex vivo expanded donor or third-party MSCs prolonged
survival ofhistoincompatible skingrafts inbaboons [109].
MSCS IN ANIMAL MODELS OF HCT
Inbred Mice Models
Models of engraftment
In bone marrow niches, MSCs act as paracrine
mediator, producing chemokines, cytokines, and extra-
cellular matrix proteins that support survival, prolifera-
tion, and engraftment of hematopoietic stem cells
[110-114]. There is little evidence thus far that MSCs
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been shown that some MSCs express the CXCR4
receptor, which might contribute to MSC homing via
stem cell–derived factor-1 gradients [115]. In contrast,
MSCs can migrate to inflammatory sites and to tumors
[116,117]. Using immunodeficient mice models of
engraftment, several groups of investigators have
demonstrated that cotransplantations of human MSCs
improved engraftment of human hematopoietic stem
(CD341) cells into nonobese severe combined
immunodeficiency (NOD/SCID) mice when low
numbers of CD341 cells were injected [118-120].
Because engraftment of allogeneic hematopoietic
cells depends on dampening immune-mediated host-
versus-graft reactions [121], Nauta et al. examined
the in vivo immunomodulatory properties of MSCs
in various murine models of transplantation [122]. Us-
ing a multiple minor histocompatibility antigen mis-
matched model (BALB/b [H-2b/b] into B6 [H-2b/b])
where B6 mice were given T cell–depleted marrows
from BALB/b mice after sublethal irradiation, the
authors observed that B6-derived MSC infusions on
days 4, 7, 10, and 14 resulted in a significant increase
in the percentage of engrafted mice (44% versus
82%; P\ .05) [122]. In contrast, all recipient B6 mice
that received transplanted BALB/b bone marrows
andBALB/b-derivedMSCs failed to engraft and devel-
oped memory T cell responses against BALB/b cells.
The same was true when only 1 single dose of BALB/
b-derived MSCs was infused. Further, the lower
engraftment when allogeneic donor MSCs were
infused was also observed in a major MHC mismatch
transplantation model (B6 bone marrows transplanted
into BALB/c [H-2d/d] recipients) (13% engraftment
versus 50%with syngeneicMSCs). Finally, the authors
observed that infusion of third-partyMSCs had no sig-
nificant impact on the engraftment of allogeneic mar-
row after sublethal irradiation. They concluded that
murine MSCs were capable of inducing immune
responses in vivo that could result in graft rejection
when donor-derived allogeneic MSCs were infused,
whereas MSCs promoted engraftment when they
were not rejected as the result of an allo-immune
response (ie, when syngeneic MSCs were infused). It
should be stressed that these observations in murine
models differ from what has been observed in human
allogeneic HCT recipients, where MSC infusions
were only weakly immunogenic, because HCT recipi-
ents givenMSCs showed no response to infusedMSCs
before and up to 6 months after MSC infusion [85].
Models of GVHD
A number of studies have analyzed the ability of
MSCs to prevent GVHD in mice (Table 1). However,
it should be stressed that murine and humanMSCs dif-
fer in several instances. First, the in vitro immunosup-
pressive activity of murine MSCs seems to be lowerthan that of human MSCs [123]. Second, ex vivo pro-
duction of purified MSCs is much faster in humans
than in mice [123]. Third, murine MSCs are more
prone to undergo immortalization and transformation
in culture than humanMSCs [124]. Fourth, in contrast
to human MSCs, murine MSCs failed to express func-
tional indoleamine 2,3 dioxygenase enzyme, even with
maximal cytokine activation [125].
Using an MHC mismatched model of GVHD
(C57BL/6 [H-2b/b] into BALB/c [H-2d/d]), Sudres
et al. [123] observed that MSCs (derived from bone
marrows from C57BL/6 mice) added to bone marrow
transplants at MSC/T cell ratios of 1 of 1 to 8 of 1
(a ratio that provided strong inhibition of T cell
in vitro) did not decrease in vivo T cell activation
and failed to decrease GVHD incidence or severity
[123]. The lack of effect of MSCs was not because of
rejection of MSCs, because MSCs could be detected
up to 6 days after transplantation in bone marrows
and lungs of grafted animals. However, only traces of
MSCs could be detected in GVHD target organs,
perhaps explaining their failure to suppress GVHD.
In contrast to what was observed by Sudres et al.
[123], Li et al. [126] showed that MSCs added to
bone marrow transplants at MSC/splenocyte cell ra-
tios of 1 of 10 or 1 of 20 somewhat delayed aGVHD
in a similar GVHD model (C57BL/6 [H-2b/b] into
BALB/c [H-2d/d]), although all transplanted mice
eventually died from GVHD within the first 13 days
after transplantation.
Using another MHC mismatched model (BALB/c
[H-2d/d] into C57BL/6 [H-2b/b]), Polchert et al. [127]
observed that bonemarrow BALB/c-derivedMSCs in-
fused i.v. on day 0 failed to decrease GVHD incidence
or severity, confirming observations by Sudres et al.
[123]. However, MSCs given either on day 2 or on
day 20 after transplantation significantly improved
survival and decreased GVHD symptoms [127].
Although mice given 0.1  106 MSCs or 0.5  106
MSCs on day 2 had similar survival, animals given
MSCs on day 20 had higher survival when given
0.5  106 MSCs than when given 0.1  106 MSCs.
This could be because of a higher number of activated
T cells present on day 20 (at the time of GVHD) than
on day 2 after HCT. Interestingly, interferon-g activa-
tion of MSCs was required to prevent GVHD in that
model, and interferon-g activated MSCs given on
day 0 were able to abrogate GVHD mortality.
The ability of parental or recipient MSCs i.v. infu-
sion to prevent GVHD in a haploidentical model of
GVHD (C57BL/6 [H-2b/b]/ CB6F1 [H-2 b/d]) was
assessed by Prighozina et al. [128]. Repeated i.v. infu-
sions of parental or recipient bone marrow MSCs
(0.5-5 105MSC/mice) ondays 0, 7, and14 after trans-
plantation failed to reduce GVHD-related mortality.
Yanez et al. [129] compared the properties of
human adipocyte-derived MSCs and human bone
Table 1. Impact of MSC Infusions in Murine Models of GVHD
Authors (References) Mice Model MSC Source, Dose, and Schedule of Administration Main Observations
Sudres et al. [123] C57BL/6 (B6; H-2b/b)/ BALB/c (H-2d/d) MSCs derived from BM from C57BL/6 mice and given on day 0 at
an MSC/T cell ratio from 1/1 (5  105MSC and CD3+ T cells) to
8/1.
- MSCs cotransplantation failed to prevent GVHD.
- On day 6 after transplantation, MSCs were mainly present in the
bone marrows and lungs (where they were trapped), whereas
only traces of MSCs were detected in target organs of GVHD
and in secondary lymphoid organs.
Li et al. [126] C57BL/6 (B6; H-2b/b)/ BALB/c (H-2d/d) MSCs derived from BM from C57BL/6 mice and given on day 0 at
an MSC/splenocyte cell ratio from 1/10 (2 106 MSC and 2 107
splenocytes) to 1/1000.
- MSCs given at the dose of 2  106 or 1  106 cells somewhat
delayed aGVHD, but all mice died of GVHDwithin the first 13 days
after transplantation.
- MSC infusion increased the number of T cells in secondary
lymphoid organs and decreased the migration of effector T cells
in GVHD target tissues.
Polchert et al. [127] BALB/c (H-2d/d)/ C57BL/6 (B6; H-2b/b) BM-derived MSCs from BALB/c mice were infused at the doses
of 1  105 or 5  105 at various timing after transplantation.
- MSCs infused on day 0 prevented GVHD only when previously
activated with high-doses of IFN-g (500 U/mL).
- MSCs infused on day 2 or on day 20 at the dose of 1  105 or
5  105 MSCs/mice each prolonged survival.
- MSCs infused on day 2 failed to prolong survival when splenocytes
from IFN-g knockout mice were used to induce GVHD.
Prigozhina et al. [128] C57BL/6 (B6; H-2b/b)/CB6F1 (H-2
b/d) BM-derived MSCs from C57BL/6 or CB6F1 infused on days 0, 7,
and 14 at the dose of 0.5  105 or 5  105 MSCs/mice.
- Neither parental nor recipient MSCs decreased GVHD.
Yanez et al. [129] C57BL/6 (B6; H-2b/b) (107 BM cells + 2  107
splenocytes)/ B6D2F1 (H-2b/d)
5  104 MSCs derived from adipose tissue from B6D2F1 infused
on days 0, 7, and 14 or on days 14, 21, and 28.
- Decreased GVHD and prolonged survival in mice given MSCs
on days 0, 7, and 14.
- No impact of MSCs when administered on days 14, 21, and 28.
Badillo et al. [130] C57BL/6 (B6; H-2b/b) (107 BM cells + 3  107
splenocytes)/ B6 x BALB/c F1 (H-2b/d)
1.5  105-1  106 MSCs/mice derived from bone marrows from
C57BL/6 mice infused on single dose either on day 0, 2, 10, or
on day 21 after transplantation, or 0.5  105 MSCs infused on
days 0, 7, and 14 after transplantation (serial infusion).
- MSCs failed to prevent GVHD and to prolong survival in all
tested schedules.
Christensen et al. [131] - UBI-GFP/BL6 (H-2b/b)/ BALB/c (H-2d/d) and
- UBI-GFP/BL6 (H-2b/b)/ BALB.B (H-2b/b)
4 105 MSCs derived from bone marrows from UBI-GFP/BL6 mice
infused i.p. on day 1 after transplantation.
- MHC-mismatched model: MSC infusion postponed death from
GVHD from 6.6 ± 0.13 days to 12.0 ± 1.7 days (P < .001),
but did not prevent death from GVHD.
- Minor histocompatibility mismatched model: MSC infusion
postponed mortality from GVHD from 31.6 ± 2.6 days
to 50.5 ± 8.8 days (P < .05) and prevented death from GVHD
in 30% of MSCs infused mice.
Tisato et al. [132] Human PBMC (20  106) i.v./ NOD/SCID mice 3  106 human cord blood–derived MSCs injected on day 0, or on
days 0, 7, 14, and 21, or 4 times every 3 days at the time of GVHD.
- Cotransplantation of MSCs on day 0 only failed to prevent GVHD.
- MSC infusions on days 0, 7, 14, and 21 prevented human
lymphocyte expansion and GVHD.
- MSC infusions at the time of GVHD failed to resolve GVHD.
Bruck et al.* [133] Human PBMC (30  106) i.p./ NOD/SCID/gcnull mice 3  106 human bone marrow-derived MSCs injected in i.p. on
days 0, 7, 14, and 21 after PBMC injection.
- Repeated infusions of MSCs failed to prevent death from GVHD.
BM indicates bone marrow; INF, interferon.
*Published only in an abstract form.
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Biol Blood Marrow Transplant 18:822-840, 2012 827MSCs and GVHDmarrow–derivedMSCs, and then assessed the ability of
murine adipocyte-derivedMSCs to prevent GVHD in
an MHC-haploidentical model of GVHD (C57Bl/6
[H-2b/b] into B6D2F1 [H-2b/d]) [129]. The authors ob-
served that human adipocyte-derived and bone
marrow–derived MSCs exhibited comparable pheno-
type and immunoregulatory properties. Further, mu-
rine adipocyte-derived MSCs given i.v. at the dose of
5  104 MSCs (MSC/splenocyte ratio of 1:400) on
days 0, 7, and 14 after transplantation improved
survival and decreased GVHD. In contrast, MSCs
given at the dose of 5  104 MSCs on days 14, 21,
and 28 failed to prevent GVHD mortality. The
authors concluded that adipocyte-derivedMSCs could
effectively control MHC-haploidentical GVHD in
mice, but that the timing and the number of MSC
infusions played a major role in GVHD prevention.
Badillo et al. [130] assessed the ability of bone
marrow–derived MSCs to prevent or treat GVHD in
an MHC-haploidentical model of GVHD (C57Bl/6
[B6; H-2b/b] into B6x BALB/cF1 [H-2b/d]). MSCs in-
fused at various dose and timing after transplantation
failed to prevent or treat GVHD, or to prolong
survival.
Christensen et al. [131] examined the impact of tim-
ing and dose of donor-derived MSCs on kinetics of
GVHD in 2 murine models of GVHD (MHC-mis-
matched model: UBI-GFP/BL6 [H-2b/b] into BALB/c
[H-2d/d], and minor histocompatibility mismatched
model: UBI-GFP/BL6 [H-2b/b] into BALB.B [H-2b/b])
[131]. Bone marrow–derived MSCs from UBI-GFP/
BL6 mice were infused i.p. at the doses of 4  105 or
1  106 MSCs/mice. In the MHC-mismatched model,
i.p. infusion of 4 105 donorMSCs/mice on day 1 after
transplantation delayed GVHD mortality from 6.6 6
0.13 days to 12.0 6 1.7 days (P\ .001). In the minor
histocompatibility mismatched model, i.p. infusion of
4 105 donorMSCs/mice onday 1 after transplantation
postponed mortality fromGVHD from 31.66 2.6 days
to 50.5 6 8.8 days (P \ .05), and even prevented
death from GVHD in 30% of MSCs infused mice.
Interestingly, mice given 1  106 donor MSCs/mice
i.p. on day 1 died sooner than controls (21.7 6 1.2
days versus 31.6 6 2.6 days, P\ .01). Finally, MSC
infusions were unable to resolve established GVHD.
Tisato et al. [131] assessed the ability of cord
blood–derived human MSCs to prevent GVHD in
a model of xenogeneic GVHD into NOD/SCID
mice. All mice given 20 106 human peripheral blood
mononuclear cells (PBMCs) i.v. after sublethal irradi-
ation (2.5 Gy TBI), and no MSCs developed signs of
xenogeneic GVHD. Similar results were seen in mice
receiving a single i.v. injection of human MSCs (3 
106 MSCs/mice) on day 0. In contrast, mice given
4 doses of MSCs at weekly intervals (total dose of
12  106 MSCs) did not develop GVHD and had sig-
nificantly less activated human T cells than mice notgiven MSCs or given MSCs only at day 0. However,
no therapeutic benefit was observed when MSCs
were administered at onset of GVHD.
Finally, we evaluated the ability of bone marrow–
derived human MSCs to prevent xenogeneic GVHD
in NOD/SCID/gC
null (NSG) mice infused i.p. with
30  106 human PBMC after sublethal irradiation
(n 5 30) [133]. Although MSCs exhibited potent
immunosuppressive properties in vitro, i.p. injection
of 3  106 bone marrow–derived human MSCs at
time of PBMC injection and on days 7, 14, and 21
thereafter (for a total of 12  106 MSCs) failed to
reduce in vivo T cell proliferation and failed to prevent
death from GVHD.
Taken together, these studies suggest that a single
injection of (nonactivated) MSCs given on day 0 failed
to prevent GVHD in most mice models, whereas
repeated MSCs injections at the time of and after
transplantation showed clinical benefits in some (but
not all) GVHD models, depending on the origin of
MSCs, the timing of infusion, as well as the dose of
MSCs infused. Further, engraftment of MSCs at sites
of GVHD was either very low or completely absent,
suggesting that beneficial effects of MSCs were not
mediated by differentiation of MSCs at the site of
GVHD reactions.
Preclinical Dog Model
Although mouse studies have proven unevaluable
for studying GVHD biology and physiology
[134,135], it has been known since the late 1960s that
GVHDreactions inhumans and random-bred large an-
imals aremore violent than in inbred rodents [136].The
wide genetic diversity, well-mixed gene pool, and the
outbred nature of dogs have made them a particularly
suitablemodel for preclinical transplantation studies in-
cluding understanding of graft-versus-host and host-
versus graft reactions, anddeveloping clinically relevant
regimens for allogeneic HCT and for GVHD preven-
tion [136]. This prompted Lee et al. [137] and Miel-
carek et al. [94] to investigate the impact of MSC
infusions on both engraftment and GVHD in dogs.
As observed with human bone marrow–derived
MSCs, canine bone marrow–derived MSCs could be
obtained after 2 to 3 weeks of culture, expressed
CD29, CD44, CD73, CD90, and CD106 but not
CD45, CD34, or CD14, and strongly inhibited mixed
lymphoid reactions independently of dog leukocyte-
antigen (DLA) matching between MSCs and effector
cells, and independently of cell-to-cell contact but
requiring communication between PBMCs and
MSCs [137]. However, in contrast to human MSCs,
dog MSCs did not express CD105.
Mielcarek et al. [94] infused 111In-labeled MSCs
into a beagle and analyzed their in vivo distribution us-
ing a gamma camera. Although 111In-labeled MSCs
accumulated in the lung immediately after infusion,
Figure 1. (A) Cumulative incidents of graft rejection in dogs given
DLA-identical marrows after 1 Gy TBI and postgrafting immunosup-
pression with cyclosporin plus mycophenolate mofetil (or rapamycin)
according to various additional approaches of cellular therapy [Ctrl,
no additional therapy, n 5 11 [138,139]; MSC, infusions of
mesenchymal stem cells (1.1-1.8  106 MSC/kg) on days 0 and 35
after transplantation, n 5 4 [137]; DLI, donor lymphocyte infusion
(1-2.6 108 CD3/kg) around day 35 with or without preceding pentos-
tatin, n5 9 [145]; CTLA4Ig, injection of donor PBMC before transplan-
tation with costimulation blockade with CTLA4Ig, n 5 5 [141]; and
injection of donor PBMC before transplantation with costimulation
blockade with CD154 antibodies, n 5 6 [142]. Although CTLA4Ig
(P\ 0.001), CD154ab (P 5 0.001), and DLI (P 5 0.001) somewhat
increased the rate of stable engraftment, graft rejection occurred at
a similar rate in dogs given MSCs and in control dogs (P 5 .7). (B)
Incidents of graft rejection and of GVHD as well as median number
of days of survival in dogs given DLA-haploidentical marrows after 9.2
Gy TBI with or without added MSC infusions (2-3 infusions/week of
1-30  106 MSC/kg) after transplantation [94].
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distributed to liver and spleen where residual label
could be detected up to 9 days after infusion. Weaker
signals were detected in gut and bone marrow.
Model of engraftment in the MHC-identical
setting after nonmyeloablative conditioning
Consistent and sustainedmixed donor–host chime-
rism has been achieved in dogs given DLA-identical
marrows after a small doseof 2GyTBI andpostgrafting
immunosuppression with cyclosporine for 35 days plus
eithermycophenolatemofetil (MMF) or rapamycin (si-
rolimus) for 28 days [138,139].When theTBI dose was
decreased to 1 Gy in this setting, all dogs engrafted
initially but eventually experienced graft rejection,
demonstrating a delicate balance between host-
versus-graft and graft-versus-host reactions [138,139].
The most likely role of TBI in that model was host
immunosuppression rather than creation of marrow
space (reviewed in [140]). Indeed, successful sustained
allografts were accomplished in dogs given 1 Gy TBI
conditioning, which had been ‘‘sensitized’’ against
donor PBMC in the presence of T cell postimulatory
blockade with CTLA4-Ig [141] or with an antibody
directed against CD154 [142]. Also, dogs conditioned
with 4.5 Gy irradiation to the cervical, thoracic, and
upper abdominal lymph node chain instead of TBI
[143], and those conditioned with T cell ablation using
a bismuth-213-labeled (a emitter) anti-T cell receptor-
ab monoclonal antibody [144] had sustained marrow
engraftment. Further, a single donor lymphocyte infu-
sion given 28 to 36 days either with (n5 5) or without
(n5 4) preceding treatment with the immunosuppres-
sive drug pentostatin allowed sustained engraftment in
3 of 9 dogs given DLA-identical marrows after 1 Gy
TBI and postgrafting immunosuppression with cyclo-
sporine and MMF [145].
Based on these observations, Lee et al. [137] inves-
tigated whether donor bone marrow–derived MSC
infusions on the day of marrow grafting (1.2-1.8 
106 MSCs/kg) and on day 35 (the day of cyclosporine
discontinuation, 1.1-1.3  106 MSCs/kg) prevented
graft rejection in dogs given DLA-identical marrows
after 1 Gy TBI and postgrafting immunosuppression
with cyclosporin and MMF. Even though the MSCs
infused strongly inhibited lymphocyte culture reactiv-
ity in vitro (median inhibition index of 71%, range:
32%-92%), they failed to prevent graft rejection
in vivo in all 4 studied dogs (Figure 1A).Model of GVHD in the MHC-haploidentical
setting
Mielcarek et al. [94] assessed the ability of canine
MSCs to prevent graft rejection and GVHD in dogs
given marrows from DLA-haploidentical donors after
9.2 Gy TBI without pharmacologic postgraftingimmunosuppression. MSCs consisted of either a com-
bination of 3 different immortalized MSC lines (15-
30  106 MSCs/kg/day administered i.v. 2-5 times/
week, n 5 12) or third-party primary MSCs (1  106
MSCs/kg/day administered i.v. 3 times/week, n 5 3).
Graft rejection occurred in 7 of 14 analyzable dogs
(including 2 of 3 dogs given third-party primary
MSCs), whereas the 7 remaining dogs succumbed to
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sults are comparable to what has been achieved in dogs
given DLA-haploidentical marrows after 9.2 Gy TBI
without MSCs administration (Figure 1B). Interest-
ingly, without previous ex vivo expansion of stromal el-
ements, MSCs could not be detected by polymerase
chain reaction in the dog tissues at necropsy. Further,
MSCs could be detected in the bone marrow, spleen,
and lung of only 2 of 6 dogs after previous ex vivo ex-
pansion of stromal elements collected in the dog tis-
sues at the time of necropsy, suggesting that the
frequency of tissue-based MSCs was very low.
Taken together, these data show that, although
canine MSCs had phenotype and immunosuppressive
abilities comparable to human MSCs, they failed to
promote engraftment or prevent aGVHD, even when
repeated injections of high doses of MSCs were used.MSCS IN HUMANS
In the HCT setting, MSCs have been infused with
the aims of promoting engraftment, preventing/treat-
ing GVHD, or promoting healing of regimen-related
toxicity (recently reviewed in [146]). As observed in
murine models, there has been no evidence in humans
that i.v. injection of MSCs was followed by MSCs
engraftment and differentiation in organs affected by
GVHD. Instead, it has been postulated that MSC
infusions could modulate inflammation and immune
responses by secreting soluble mediators, and perhaps
by inducing immune tolerance because activated
MSCs express HLA-class II molecules without
expressing costimulatory molecules [97,147].
Importantly, i.v. infusion of MSCs appeared to be
safe, with no infusional toxicity (and, in particular, no
report of pulmonary embolism), MSC-derived malig-
nancy, or ectopic tissue formation being reported
thus far in any of the studies discussed below. How-
ever, long-term follow-up of patients given MSCs is
important in order to detect possible late effects.
Ex Vivo Expansion of Human MSCs
It should be emphasized that humanMSCs are not
a homogeneous population and that some properties
of human MSCs do change with increasing numbers
of cell divisions [120]. In the early 1980s, Mets et al.
observed that the cells that initially adhere to tissue
culture surfaces in early passage, low-density cultures
were spindle shaped and very rapidly proliferating
[148]. Those cells were termed type 1 cells or rapidly
self-renewing MSCs. The author then observed that
rapidly self-renewing MSCs gave rise to larger cells,
termed type 2 cells or slowly replicating MSCs. Lee
et al. [149] recently identified 2 antibodies, 1 recogniz-
ing PODXL and another recognizing CD49f, that al-
lowed identifying the early progenitors in cultures ofMSCs. PODXLhi/CD49fhi cells were more efficient
than PODXLlo/CD49flo cells both in generating
single cell-derived colonies and in differentiating in
culture, but they were less likely to produce lethal pul-
monary emboli and survived longer in the lung of
SCID mice after intravenous infusion. Unfortunately,
the impact of MSC composition (type 1 versus type 2)
on their efficacy to prevent or treat GVHD has not
been assessed thus far.
Another concern with long-term culture of MSCs
is the observation that human MSC senescence could
occur as early as after 2.6 cumulative population dou-
bling (4 ‘‘passages’’) with someMSC donors, with sen-
escent cells having lost most of their plasticity and
clonogenicity properties [150]. These data should be
kept in mind when analyzing preliminary data of
MSC infusions in humans because some studies trans-
planted MSCs after 2 to 3 passages in plates [151],
whereas in other studies, MSCs were expanded more
extensively in large bioreactors [152].
BecauseMSCs are believed to act mainly by secret-
ing soluble factors, the impact of MSC preparation
(MSC origin, culture media, type of serum supplemen-
tation, and extent of ex vivo expansion) on their ability
to produce specific soluble factors deserves further in-
vestigations. Further, given that activation ofMSCs by
IL-1 impacts on their cytokine expression and produc-
tion [153], the inflammatory status of patients at the
time of MSC infusion is also likely to influence the bi-
ological activities of MSCs.
European centers interested in clinical trials of
MSC infusion have created a European Group for
Blood and Marrow Transplantation (EBMT) ‘‘MSC
expansion consortium,’’ to define common protocols
for MSCs isolation and expansion procedures, as well
as common release criteria, enabling large-scale multi-
center trials with comparable MSC products [151].
Briefly, this procedure consists of culture of bone mar-
row adherent mononuclear cells in 10% fetal bovine
serum (FBS) containing medium. Cells are passaged
when cultures are near confluence and then are har-
vested at passage 1 to 4. Release of MSC criteria
include absence of visible clumps, spindle-shape mor-
phology, absence of contamination by pathogens, via-
bility .95%, and immune phenotyping showing
expression of CD73, CD90, and CD105 surface mol-
ecules (.90%) and absence of CD34, CD45, CD14,
and CD3 [151]. MSCs could be either infused freshly
or after cryopreservation in 10% dimethyl sulfoxide
(DMSO).
Several studies discussed below infused MSC
products termed Prochymal produced by Osiris
Therapeutics, Inc. (Columbia, MD). In 1 of these
studies, all MSCs infused (124 infusions in 12 children)
were derived from bone marrows of 4 healthy volun-
teer donors [154], suggesting quite extensive expansion
of MSCs ex vivo. Adherent cells were grown as
Figure 2. MSCs chimerism 1-192 (median 5) months after allogeneic
bone marrow or cord blood transplantation in the study reported by
Pozzi et al. [162]. MSCs were analyzed after a median of 4 passages
and were positive ($98% positivity) for CD73, CD105, CD106,
CD29, CD13, and CD44 and negative (#1%) for CD34, CD45, and
CD14. MSC chimerism was determined by amelogenin assay (in case
of female donor to male recipient) or by STR PCR. Pediat., pediatric re-
cipients; BM, bonemarrow; CB, umbilical cord blood; MC, mixed donor/
host chimerism; FRC, full recipient chimerism.
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neous cell population positive for surface antigens
including CD29, CD73, CD90, and CD105 and neg-
ative hematopoietic markers including CD14, CD34,
and CD45. The cells were cryopreserved in 5% human
serum albumin and 10% DMSO-containing medium.
Final lots were tested for potential viral pathogens,
mycoplasma, sterility, endotoxin, cell identity, purity,
and viability before being released for clinical use.
Although many regulatory agencies have not for-
bidden the use of FBS in the culture medium of
MSCs, several groups of investigators have developed
FBS-free MSC expansion protocols based on the use
of human plasma, or human platelet lysate [155-157].
For example, Lucchini et al. [156] expanded MSCs
from nucleated cells isolated from the washouts of
sealed bone marrow collection bags and filters in
platelet-lysate-containing medium. Release criteria
included: lack of detectable microbial contamination,
cell viability $90%, endotoxin levels in the final pro-
duct #5 EU/kg, normal karyotype, and inability to
grow without anchorage in a semisolid fluid. Pheno-
typing release criteria were less stringent than those
used by other groups of investigators and included
$70% expression of CD73, CD90, and CD105 and
#10% expression of CD14, CD34, and CD45.
Given that these differences in MSC isolation and
culture expansion conditions are likely to influence
MSC behavior after infusion to patients [158,159],
one should remain cautious when comparing results
of clinical studies performed with MSC products
prepared with different protocols.
Engraftment of Donor MSCs after Allogeneic
HCT
Although marrow grafts contain approximately
10,000 MSCs/kg of recipient weight [76,77], stromal
progenitor cells remain host in origin after allogeneic
HCT in adults, even after 27 years of complete donor
hematopoietic chimerism [160,161], suggesting that
donor MSCs have a limited role in reconstituting the
marrow microenvironnement after HCT in adults. In
contrast to what has been observed in adult
recipients, engraftment of donor MSCs has been
demonstrated in approximately 30% of pediatric
patients given allogeneic cord blood or marrow grafts
(Figure 2) [162]. Why MSCs sometimes engraft in
children but not in adults has remained unexplained
thus far.
Cotransplantation of MSCs and Autologous
HCT
Koc et al. [163] analyzed the safety and feasibility
of infusing bone marrow–derived autologous MSCs
in combination with autologous PBSC (containing
a median of 13.9  106 CD341 cells/kg) in 32 patientsgiven high-dose chemotherapy as treatment for breast
cancer. Expansion cultures allowed obtaining .1 
106 MSCs/kg for all patients after 2 to 6 passages.
Twenty-eight patients were given 1 to 2.2 106 autol-
ogous MSCs/kg intravenously. Clonogenic MSCs
were detected in venous blood up to 1 hour after infu-
sion in 13 of 21 tested patients (62%). No toxicities
related toMSC infusions were observed.Median times
to achieve a neutrophil count .500/mL and a platelet
count $20,000/mL were 8 days (range: 6-11 days)
and 8.5 days (range: 4-19 days), respectively. Based
on these observations, the authors concluded that
MSC infusions might have a positive impact on hema-
topoiesis after autologous HCT and should be tested
in phase III randomized studies. Unfortunately, as of
yet, no large randomized studies aimed at testing this
hypothesis have materialized.Cotransplantation of MSCs and Allogeneic HCT
A number of studies have assessed the impact of
MSC infusion at the time of HCT on engraftment
and GVHD (Table 2). Lazarus et al. [164] conducted
a study of cotransplantation of MSCs and HLA-
identical sibling marrows or PBSC after myeloablative
conditioning in 46 patients. Postgrafting immunosup-
pression consisted of cyclosporine and methotrexate
(the latest given at days 1, 3, and 6). MSCs (cultured
from bone marrow aspirates from the hematopoietic
stem cell donor) were administered 4 hours before
HCT in a dose escalation scheme at 1.0 (n 5 20), 2.5
(n 5 21), or 5.0 (n 5 5)  106 MSCs/kg. There was
no impact of the dose of MSCs infused on the speed
Table 2. Studies of Cotransplantation of Allogeneic Hematopoietic Stem Cells and MSCs in Humans
Authors [References]
No. of Patients/Study
Phase Stem Cell Source
MSC
Dose  106/kg Main Observations
Lazarus et al. [164] 46/I-II, single arm BM or PBSC from HLA-identical
siblings
1-5 - MSCs cotransplantation feasible and safe.
- MSCs donor chimerism (>1%) was evinced in
2 of 18 patients in whom BM MSCs
chimerism was assessed after HCT.
MacMillan et al. [165] 15/I-II, single arm Unrelated cord bloods 0.9-5.0* - MSC cotransplantation feasible and safe.
Ball et al. [166] 14/I-II, single arm HLA-disparate CD34+ cells 1-3.3 In comparison to a group of 47 matched
historical controls:
- faster leukocyte (and NK cell) recovery
- a trend for lower risk of graft rejection
(0% versus 15%)
Bernardo et al. [167] 13/I-II, single arm Unrelated cord bloods 1-3.9 In comparison to a group of 39 matched
historical controls:
- comparable risk of graft rejection
- less grade III-IV aGVHD (P 5 .05)
- similar survival and relapse incidence
Ning et al. [168] 30 (10 given MSC);
II randomized
PBSC and/or BM from HLA-identical
siblings
0.03-1.5 - Lower incidence of grade II-IV aGVHD but
higher risk of relapse (P 5 .02) in MSC
patients (n 5 10) than in controls (n 5 15).
Baron et al. [169] 20/I-II, single arm PBSC from HLA-mismatched donors 1-2 - Cotransplantation of HLA-mismatched PBSC
and third-party MSC is feasible with an
acceptable nonrelapse mortality
(10% at 1 year).
BM indicates bone marrow.
*Three patients received a second MSC infusion on day 21.
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II-IV and grade IV aGVHDwere 28%and 4%, respec-
tively, whereas 22% of patients who survived at least
90 days after HCT experienced extensive cGVHD.
Two-year overall survivals (OS) and progression-free
survivals were 78% and 53%, respectively. Interest-
ingly, the authors were able to demonstrate MSCs
donor chimerism in only 2 of 18 patients in whom
MSCchimerismwas assessed fromposttransplantation
bone marrow aspirates.
In an attempt to speed hematopoietic recovery af-
ter umbilical cord blood transplantation, 15 pediatric
patients with high-risk acute leukemia were enrolled
by MacMillan et al. [165] in a phase I-II clinical trial
in which MSCs from HLA-haploidentical parental
donors were infused at the time of transplantation.
Seven patients did not receive MSC infusions because
transplantation did not occur (n 5 3) or occurred at
a different center (n 5 1) or because of insufficient
MSC availability at the time the patient was ready for
transplantation (n 5 3). The median number of
MSCs infused on day 0 was 2.1  106 (range: 0.9-
5.0 106)MSCs/kg, whereas 3 patients received a sec-
ond dose ranging from 0.06 to 5  106 MSCs/kg on
day 21 after HCT. The 8 MSC patients achieved
neutrophil engraftment at a median of 19 days (range:
9-28 days) after HCT. Probability of platelet engraft-
ment was 75%, at a median of 53 days (range: 36-
98 days) after HCT. Three of 8 patients experienced
grade II aGVHD, whereas no patient developed
cGVHD. Interestingly, no evidence of MSC donor
chimerism was detectable in any patient at any time
point after HCT.Ball et al. [166] cotransplanted donor MSCs in
14 children undergoing transplantation of CD341
selected cells from HLA-disparate related donors.
MSCs (isolated from HSC donor bone marrows)
were collected at passage 3 or less and given at a dose
of 1.0-3.3  106 cells/kg. No MSC infusion-related
toxicity was observed. All 14 patients achieved sus-
tained engraftment, whereas graft failure occurred in
7 of 47 comparable historic patients not given MSCs
(P 5 .14). Further, counts of NK cells were higher in
MSC-treated than in historical patients 1 month after
HCT (497 versus 252/mL, P5 .02). The authors con-
cluded that MSC cotransplantation might reduce the
risk of graft failure after allogeneic HCT with HLA-
disparate donors, possibly because of their immuno-
suppressive effects on recipient immune cells having
survived the conditioning regimen.
The same group of investigators cotransplanted
parental HLA-disparate MSCs in 13 children with
hematologic disorders undergoing unrelated cord
blood transplantation after myeloablative condition-
ing [167]. HCT outcomes were compared with those
observed in a cohort of 39 matched historic controls.
The cumulative incidence of graft rejection was 15%
in the MSC group versus 3% in the historic group
(NS), whereas the tempo of neutrophil and platelet
engraftments was comparable between the 2 groups.
The incidence of grade III-IV aGVHD was 0% in
the MSC group versus 26% in the historic group
(P 5 .05), whereas the cumulative incidence of
cGVHD was 0% in the MSC group versus 11% in
the historic group (NS). Finally, 3-year OSs were
63% and 64% in the MSC and control groups,
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of relapse were 25% and 23%, respectively.
Ning et al. [168] performed a randomized clinical
trial including 30 patients given marrows and/or
PBSC from HLA-identical siblings with (n 5 15) or
without (n5 15) addedMSCs after myeloablative con-
ditioning. The median dose of MSCs given was rela-
tively low (3.4 [range: 0.3-15.3]  105/kg), and the
authors failed to grow sufficient numbers of MSCs in
5 of the 15 patients randomized to the MSC arm.
The authors compared the outcomes of the 10 patients
givenMSCs with those observed in the 15 patients ran-
domized in the control arm. The only patient with
acute myelogenous leukemia in relapse at transplanta-
tion was in the MSC arm. One of 10 patients in the
MSC arm versus 8 of 15 in the control arm experienced
grade II-IV aGVHD. However, patients given MSCs
had higher risk of relapse (60% versus 20% at 3 years;
P 5 .02), and lower disease-free survival (30% versus
67% at 3 years; P5 .035) than those in the control arm.
Baron et al. [169] reported the results of a pilot
study analyzing the safety of MSC cotransplantation
in 20 patients given HLA-mismatched PBSC after
fludarabine and 2 Gy TBI [169]. MSCs were collected
after 3 or less passages and given at doses of 1-2 
106 MSCs/kg. The primary endpoint was safety,
defined as a 100-day incidence of nonrelapse mortality
\35%. The 100-day cumulative incidence of grade II-
IV aGVHD was 35%, whereas 65% of the patients
experiencedmoderate/severe cGVHD.One-year non-
relapse mortality (10%), relapse (30%), OS (80%),
progression-free survival (60%), and 1-year incidence
of death from GVHD or infection with GVHD
(10%) were encouraging. Transplantation outcomes
in these 20 patients were compared with those
observed in a historic group of 16 patients given
HLA-mismatched PBSC (but no MSCs) after the
same nonmyeloablative conditioning. One of 20 pa-
tients in the MSC group versus 0 of 16 patients in
the historic group experienced graft rejection. The 1-
and 2-year probabilities of dying from GVHD or in-
fection while on treatment for GVHD were 10% and
10%, respectively, in the MSC group, versus 31%
and 38%, respectively, in the historic group (P 5 .04).
Taken together, these data suggest that MSC
cotransplantation does not seem to promote engraft-
ment or prevent graft rejection in the setting of
T cell–replete transplantation, whereas it might be
beneficial in the setting of HLA-disparate T cell–
depleted HCT, perhaps because of their immuno-
suppressive effects on recipient immune cells that
survived the conditioning regimen. Further, 3 studies
[167-169] observed lower risks of aGVHD in patients
cotransplanted with MSCs than in historic (n 5 2) or
concurrent (n 5 1) controls, suggesting that MSCs
might help reduce aGVHD. However, these
observations should be taken with some caution giventhe small number of patients included in these pilot
studies. Prospective double-blind randomized studies
are ongoing in order to more definitely assess the im-
pact of MSC cotransplantation on GVHD incidence
and severity.
MSCs as Front-Line Treatment for Grade II-IV
aGVHD
As mentioned above, corticosteroids produce
durable complete responses in 20% to 75% of the pa-
tients with grade II-IV aGVHD [66-68] and less in
patients with lower gut aGVHD [68]. Many attempts
at intensifying the front-line treatment for grade II-
IV aGVHD failed. Specifically, the addition of ATG,
daclizumab, etanercept, denileukin diftitox (denileu-
kin), or pentostatin to methylprednisolone failed to
significantly improve response rates, and were often
associated with higher transplant-related mortality
[170-172]. A phase II 4-arm randomized study was
recently performed with the aim of identifying the
most promising agent (in addition to standard cortico-
steroids) for initial therapy for grade II-IV GVHD
[172]. Patients were randomized to receive methyl-
prednisolone 2 mg/kg per day plus etanercept,
MMF, denileukin, or pentostatin. Day 28 complete re-
sponse rates were etanercept 26%, MMF 60%, deni-
leukin 53%, and pentostatin 38%, suggesting that
MMF plus corticosteroids was the most promising
regimen to compare against corticosteroids alone in
a definitive phase III trial.
A recent randomized multicenter phase II study
has evaluated 2 different doses of MSCs (Prochymal)
given in combination with standard corticosteroid
therapy for the initial treatment of aGVHD [152].
MSCs derived from 6 different donors were expanded
for a total of 5 cell passages. Thirty-two adult patients
with grade II (n 5 21), grade III (n 5 8), or grade IV
(n 5 3) aGVHD were randomized to receive 2 doses
of either 2 or 8 million MSCs/kg each in combination
with corticosteroids. One patient withdrew consent on
study day 10 and was not included in the analysis. The
first MSC infusion was given within the 48 hours fol-
lowing diagnosis of grade II-IV aGVHD, whereas
the second MSC infusion was given 3 days after the
first. A total of 62 MSC products were infused.
Ninety-four percent of patients achieved complete
(77%) or partial (16%) responses to MSCs and corti-
costeroids. Interestingly, the response rates were sim-
ilar in patients given 2 or 8 million MSCs/kg
(Figure 3A), although the trial was not designed to
detect a potential difference between the 2MSC doses.
The authors concluded that the addition of MSCs to
corticosteroids might induce a high response rate in
patients with grade II-IV aGVHD, and that a dose of
2  106 MSC/kg should be tested in a phase III
placebo-controlled trial. Preliminary results of such
a randomized multicenter phase III trial with injection
Figure 3. (A) Complete response (CR), partial response (PR), and no
response (NR) rates in patients given methylprednisolone (2 mg/kg) plus
MSCs (prochymalR) at the dose of 2  106/kg (n5 16) or of 8  106/kg
(n 5 15) as first-line treatment for grade II-IV aGVHD [152]. A second
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versus placebo in addition to standard corticosteroid
therapy as primary treatment for patients with grade
II-IV aGVHDhave been released (although the results
of final analysis are pending); the trial failed to reach
the primary endpoint of durable complete response
$28 days [173].
MSCs as Treatment for Steroid-Refractory
aGVHD
Although dynamics of treatment responses differ
between target organs (faster improvement in skin
than in liver or gut aGVHD), criteria for steroid refrac-
tory GVHD have included: progression of GVHD on
day 3 after initiation of steroids, no improvement of
GVHD on day 7 after initiation of steroids, absence
of complete resolution of aGVHD on day 14 after
initiation of steroids, and/or relapse of aGVHDduring
or after steroid taper.
Based on the immunosuppressive abilities ofMSCs,
and on the apparent safety of infusion of ex vivo ex-
panded MSCs, Le Blanc et al. [174] infused such cells
in a 9-year-old boy who had refractory grade IV gut
and liver aGVHD after HLA-matched unrelated
HCT. Although his GVHD was refractory to
(methyl)prednisolone, cyclosporine, infliximab, and
daclizumab, infusion of 2  106 MSCs/kg from his
HLA-haploidenticalmother resulted in remarkable im-
provement, with normalization of stools and decline in
bilirubin levels. However, long-term tolerance was not
induced by MSC infusion because GVHD recurred
after discontinuation of postgrafting immunosuppres-
sion, although, remarkably,GVHDsymptoms resolved
again after a second MSC infusion. This case report
suggested that MSC infusion could be helpful in
selected patients with steroid-refractory aGVHD.
The Developmental Committee of the European
Group for Blood and Marrow Transplantation [151]
reviewed data from 55 patients given MSCs (median
dose 1.4 [range: 0.4-9]  106 MSCs/kg) as treatment
for steroid-refractory grades II (n 5 5), III (n 5 25),
or IV (n 5 25) aGVHD in a phase II study. No sideinfusion of MSCs at the same dose was done 3 days following the first
MSC infusion. (B) Percentage of responses to MSC infusion (27 patients
received 1 infusion, 22 received 2 infusions, and 6 received$3 infusions
of a median dose of 1.4 [range: 0.4-9]  106 MSCs/kg) in adults or chil-
dren with steroid refractory aGVHD reported by Le Blanc et al. (EBMT
survey) [151]. (C) Complete response rate according to the organ af-
fected in 59 pediatric patients with steroid-refractory aGVHD treated
with MSCs (produced by Prochymal; 8 infusions of 2  106 MSC/kg
over 4 weeks followed by an additional 4 infusions administered weekly
after day 28 in patients who had a partial response) (this study has been
reported only in an abstract form [176] thus far). (D) Overall complete
or partial response rates in patients with steroid-refractory grade II-IV
aGVHD treated by second-line therapy with added MSCs (produced
by Prochymal; 8 infusions of 2  106 MSC/kg over 4 weeks followed
by an additional 4 infusions administered weekly after day 28 in patients
who had a partial response) or placebo (this study has been reported
only in an abstract form [178] thus far).
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patients received 1 infusion, 22 received 2 infusions,
4 received 3 infusions, 1 received 4 infusions, and 1 re-
ceived 5 infusions (total of 92 infusions). MSC donors
were either HLA-identical siblings (n 5 5), HLA-
haploidentical relatives (n 5 18), or third-party
HLA-mismatched individuals (n 5 69). Among the
55 patients, 30 had complete responses and 9 showed
improvement. Responses were somewhat more fre-
quent in children than in adults (Figure 3B; P 5 .07).
Median time fromMSC infusion to complete response
was 18 (range: 3-63) days. Three patients had recur-
rent malignant disease and 1 developed de novo acute
myelogenous leukemia of recipient origin. Complete
responders to MSCs were more likely to be alive 2
years after HCT than patients with partial or no re-
sponses (52% versus 16%; P 5 .018). Interestingly,
in the subset of patients given MSCs at the Karolinska
Institutet, achievement of responses correlated to the
number of MSC expansion passages. Specifically,
patients given first- (n5 1) or second- (n5 7) passage
MSCs had a higher response rate and a higher OS
(50% versus 8% at 1 year, P 5 .02) than those given
MSCs from passage 3 to 4 (n 5 14) [175].
Prasad et al. [154] reported the results of amulticen-
ter compassionate protocol evaluating the safety and ef-
ficacy of MSC (Prochymal) infusions in 12 children
with severe steroid-refractory aGVHD. MSCs (8 
106 cells/kg/dose in 2 patients and 2  106 cells/kg/
dose in the 10 remaining patients) were scheduled to
be infused twice a week for 4 weeks, whereas partial
andmixed responders received subsequentweekly ther-
apy for 4 weeks. At the time of firstMSC infusion, 5 pa-
tients had grade III and 7 patients grade IV
gastrointestinal aGVHD. All 12 patients were steroid
refractory and had failed a median of 3 (range: 2-5)
other immunosuppressive therapies. A total of 124
MSC doses were administered with a median of 8
(range: 2-21) doses per patient. At day 32 after first
MSC infusion, 9 patients had complete (n5 1) or par-
tial (n 5 8) responses, whereas overall, 9 patients
achieved complete (n5 7) or partial (n5 2) responses.
Two-year survival from firstMSC infusion was 40% in
the whole group (68% for the 7 patients who achieved
complete responses, whereas the 5 patients who failed
to achieve complete responses died within 100 days af-
ter first MSC infusion). The same group of investiga-
tors recently reported, in abstract form, data from 59
children with grade II (n 5 6), grade III (n 5 20), or
grade IV (n 5 33) steroid-refractory aGVHD given
MSCs (Prochymal) under a Food and Drug Adminis-
tration expanded access program [176]. Patients re-
ceived 8 infusions of 2  106 MSC/kg over 4 weeks,
with an additional 4 infusions administeredweekly after
day 28 in patients who had partial responses. At day 28,
overall response rate (defined as organ improvement of
$1 stage without worsening in any other) was 64%,whereas 17%of patients had stable disease ormixed re-
sponses, and 19% had GVHD progression. The com-
plete response rate per organ is shown in Figure 3C.
Von Bonin et al. [177] gave MSCs expanded in
platelet lysate-containing medium in 13 patients with
grade III (n5 2) or grade IV (n5 11) steroid refractory
aGVHD. Median dose of MSCs was 0.9 (range: 0.6-
1.1)  106/kg, and median number of MSC infusions
was 2 (range: 1-5). MSC products had a median purity
.97% in FACS analyses. Responses to first MSC infu-
sion were observed in only 2 of 13 patients (1 complete
response and 1 partial response on day 28 after first
MSC infusion), whereas the remaining 11 patients
required additional immunosuppressive therapy.
Lucchini et al. [156] treated 11 pediatric patients
with steroid-refractory aGVHD or cGVHD by a total
of 21 MSC infusions. MSCs were isolated from the
washouts of the bone marrow collection bags and fil-
ters of a single donor and expanded in platelet lysate-
containing medium. The median MSC dose infused
was 1.2 (range: 0.7-3.7)  106/kg. Four of 11 patients
achieved complete responses, but 2 of the 4 complete
responders experienced GVHD recurrence 46 days
and 95 days after MSC infusion.
The potential role of MSCs (Prochymal) was also
evaluated in addition to standard of care, including
institutionally selected second-line treatment, in a ran-
domized (2:1) trial in patients with steroid-refractory
grade II-IV aGVHD. Patients received 8 infusions of
2  106 MSC/kg each over 4 weeks (or volume equiv-
alent for placebo), with an additional 4 infusions
administered weekly after day 28 in patients who had
partial responses. Two-hundred forty-four patients
with gastrointestinal (n 5 179), skin (n 5 144), and/
or liver (n 5 61) refractory grade II-IV aGVHD
were included. There were more patients with grade
IV aGVHD in the MSC arm (27 versus 16%), and
therefore less patients with grade II (22 versus 26%)
or III (51 versus 58%) aGVHD. Preliminary results
have been reported in abstract form [178]. The study
failed to demonstrate a significant difference in the
rate of durable (for $28 days) complete responses
between the 2 groups (primary endpoint; 35% in the
MSCs versus 30% in the placebo group (P5 .3) in in-
tent to treat analysis, and 40% versus 28% (P 5 .08),
respectively, in per protocol analysis). Looking at sec-
ondary endpoints, the overall complete or partial re-
sponse rates at day 28 were higher in the MSCs than
in the placebo group for patients with gastrointestinal
and for those with liver aGVHD, but not for those
with skin aGVHD (Figure 3D). The incidents of infec-
tion, relapse, and toxicities were similar in the MSCs
and the placebo arms. These data suggest that the ad-
dition of MSCs might help improve patients with vis-
ceral steroid-refractory GVHD without inducing
specific toxicities, but raise the question of the
durability of GVHD responses achieved with MSCs.
Biol Blood Marrow Transplant 18:822-840, 2012 835MSCs and GVHDAlthough most MSC studies in humans have
investigated marrow-derived MSCs, Fang et al. [179]
investigated the feasibility of infusing i.v. adipose
tissue-derived MSCs in patients with severe aGVHD.
Six patients with steroid-refractory grades III (n 5 2)
or IV (n 5 4) aGVHD received 1 (n 5 5) or 2 (n 5 1)
i.v. infusions of 1.0  106 MSCs/kg. No side effects
werenoted after the infusions.Fiveof 6patients achieved
complete responses, 4 of whom were still alive after
a median follow-up of 40 months after MSC infusion.
Taken together, these studies suggest that MSC
infusion has some beneficial activities in patients with
steroid-refractory grade II-IV aGVHD, although
one should be cautious about a possible bias for pub-
lishing preferentially positive studies. Further large
randomized studies are ongoing in order to better
define the impact of MSC infusion in patients with
steroid-refractory aGVHD.
MSCs as Treatment for cGVHD
There are few data published thus far on the
impact of MSC infusion in patients with cGVHD.
Zhou et al. [180] reported data from 4 patients with
severe sclerodermic cGVHD who received MSCs
from unrelated donors expanded ex vivo. MSCs were
injected into the bone marrow of the anterosuperior
iliac spine at total doses of 1-2  107 cells for 4 to 8 in-
fusions within a 22- to 52-day period. Concomitant
medications for cGVHD were individualized for
each patient and included tacrolimus, prednisolone,
thalidomide, or MMF. The doses of these medications
were tapered significantly afterMSC infusion, whereas
GVHD symptoms gradually improved in all 4 pa-
tients. More recently, Weng et al. [181] analyzed the
impact of MSC infusion in 19 patients with refractory
cGVHD. Bone marrow–derived MSCs from HLA-
matched donors or HLA-disparate third-party adult
donors and expanded in FBS-containing media were
infused i.v. at a median dose of 0.6 (range: 0.2-1.4) 
106 MSCs/kg. Patients received a median of 2 (range:
1-5) MSC infusions with a median duration between
the first and second MSC infusion of 6 months. Four-
teen of the 19 patients achieved partial (n 5 10) or
complete (n 5 4) responses after MSC infusions,
whereas the 2-year survival rate from the first MSC
infusion was 78%. Taken together, these 2 reports
might serve as the basis of prospective randomized
studies assessing the impact of MSC infusions versus
placebo in patients with steroid-refractory cGVHD.CONCLUSIONS AND PERSPECTIVES
During the last decade, therehas been a growing ex-
citement by immunologists and clinicians for the use of
MSCs in the prevention or treatment of GVHD.
Although MSCs were originally thought to improveGVHD by promoting tissue healing through
engraftment, differentiation, and long-term survival
in injured tissues, it is now accepted that MSCs do
not engraft in affected tissues but might instead
decrease inflammation and perhaps induce immuno-
modulation by secreting soluble factors. Preclinical an-
imal models of GVHD prevention or treatment by
MSCs have yielded conflicting results. Specifically,
repeated MSC infusions prevented death from
GVHD or delayed GVHD mortality in some but not
all murine models, whereas repeated MSC infusion
failed to prevent GVHD in a preclinical canine model
of transplantation. Similarly, it remains difficult to
draw definitive conclusions about the efficacy of
MSCs in thepreventionor treatment of severe aGVHD
inhumans given thatmost publishedpositive results are
from phase I-II or phase II studies, whereas a large ran-
domized study of MSC versus placebo infusions in pa-
tients with steroid-refractory aGVHD failed to
demonstrate a higher durable GVHD complete re-
sponse rate in the MSC arm. Further double-blinded
randomized studies are ongoing to assess the impact
of MSC infusion on GVHD prevention/treatment.
Other studies are focused on determining the most
efficient culture condition, dose, and schedule of
MSCadministration [182], andon analyzing the impact
on MSC infusion on immune recovery after HCT.
Because there is at yet no proof for higher efficacy of
MSC over conventional approaches for preventing or
treating GVHD, the use of MSCs should remain
restricted to patients who are included in clinical trials.ACKNOWLEDGMENTS
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